C4 Therapeutics, Inc.
CCCC
$1.54
$0.042.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 35.58M | 33.67M | 29.38M | 20.04M | 20.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.58M | 33.67M | 29.38M | 20.04M | 20.76M |
| Cost of Revenue | 110.64M | 108.52M | 105.02M | 111.20M | 117.71M |
| Gross Profit | -75.05M | -74.85M | -75.65M | -91.16M | -96.95M |
| SG&A Expenses | 42.12M | 42.05M | 40.81M | 41.42M | 42.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 152.76M | 150.56M | 145.84M | 152.62M | 159.79M |
| Operating Income | -117.18M | -116.90M | -116.46M | -132.59M | -139.03M |
| Income Before Tax | -105.19M | -105.22M | -106.59M | -124.79M | -131.21M |
| Income Tax Expenses | 131.00K | 277.00K | 1.28M | 1.28M | 1.28M |
| Earnings from Continuing Operations | -105.32 | -105.50 | -107.87 | -126.07 | -132.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -105.32M | -105.50M | -107.87M | -126.07M | -132.49M |
| EBIT | -117.18M | -116.90M | -116.46M | -132.59M | -139.03M |
| EBITDA | -115.36M | -115.13M | -114.69M | -130.80M | -137.15M |
| EPS Basic | -1.52 | -1.70 | -1.90 | -2.37 | -2.67 |
| Normalized Basic EPS | -0.96 | -1.08 | -1.18 | -1.47 | -1.69 |
| EPS Diluted | -1.52 | -1.70 | -1.90 | -2.37 | -2.67 |
| Normalized Diluted EPS | -0.96 | -1.08 | -1.18 | -1.47 | -1.69 |
| Average Basic Shares Outstanding | 277.48M | 258.12M | 237.71M | 217.96M | 198.56M |
| Average Diluted Shares Outstanding | 277.48M | 258.12M | 237.71M | 217.96M | 198.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |